News

Research Fund relaunched for 2018

We are pleased to announce that we are relaunching the our research fund for 2018. Since 2015, we have funded nine projects, all relating to axial spondyloarthritis including ankylosing spondylitis.  NASS has produced a Research Priorities 2013 - 2018 which does have a list of what NASS members feel are the most...


Could you be a NASS Trustee?

Every year at the NASS AGM and Members' Day, NASS members get the opportunity to stand for election to the Council of Management.  The Council of Management is the term we use to describe our board of trustees which is a combination of healthcare professionals and people living with AS. The...


Members Day 2018 - booking now open

We are very pleased to announce the programme and venue for our 2018 AGM and Members Day which will take place on 9 June. The full day event will take place at St Mary's University in Twickenham.  As usual the day will start with the AGM and trustee elections,...


NASS branch network wins national award

NASS are delighted to be named as winners in the 2017 AbbVie Sustainable Healthcare Patients as Partner Awards. The awards recognise those who have made an exceptional contribution to the lives of patients and contributed toward a more sustainable health service. NASS were named as winners of the category  'Supporting...


Cimzia can now be considered during pregnancy and breastfeeding

The European Medicines Agency (EMA) has approved the label change for UCB’s CIMZIA® (certolizumab pegol), making it the first anti-TNF for potential use in women with ankylosing spondylitis during both pregnancy and breastfeeding. Data submitted to regulatory authorities included first-of-their-kind clinical studies demonstrating minimal transfer of CIMZIA® through the...


NICE recommend golimumab as an option for non radiographic axial spondyloarthritis

NICE (National Institute for Health and Care Excellence) have announced golimumab (Simponi) is now recommended, within its marketing authorisation, as an option for treating severe non-radiographic axial spondyloarthritis in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs. Golimumab was already recommended by NICE for ankylosing spondylitis....


NASS funded review of research into diet and AS published

Diet and AS has always been an important issue When NASS set up our Research Fund in 2015 we wanted to fund research into whether following a particular diet or changing your diet could have an influence on your AS symptoms. Dr Tatiana Macfarlane from the University of Aberdeen...


Ankylosing Spondylitis - Not just back pain

We are delighted to launch the second in our series of three videos Ankylosing Spondylitis - Not just Back Pain, explains how AS can affect other joints, tendons and ligaments, along with other areas including the eyes, bowels and skin.   We hope you find the video interesting. Please...


Where would you like to see NASS?

We've got funding to do a few more AS & You events in 2018 - where would you like them to be - take our poll to have your say. We're 10 events into our AS & You schedule! So far they have been excellent events - everyone has learned so...


Disability Benefits Consortium launch new report

Personal Independent Payments -  Supporting those who need it most? A few years ago Personal Independence Payment (PIP) was brought in by the Government to replace Disability Living Allowance. PIP is a benefit designed to help people manage the extra costs they face because of their disability, but research...

  • First
  • Previous
  • 1
  • 2
  • Next
  • Last

Give

Join

Shop